jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

MRM breast specimen Complex Biopsy

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Modified radical mastectomy specimen.

₹1,110₹1,586

30% OFF

MRM Breast Specimen Complex Biopsy - Comprehensive Guide

  • Why is it done?
    • Diagnostic Purpose: This test involves magnetic resonance imaging (MRI)-guided biopsy of breast lesions identified as complex or suspicious on imaging. It provides definitive histopathological diagnosis of breast masses and abnormalities.
    • Primary Indications: To evaluate complex breast lesions not clearly visible on mammography or ultrasound; to assess MRI-detected abnormalities; to differentiate benign from malignant lesions; to guide treatment planning.
    • Typical Timing: Performed when imaging shows suspicious lesions requiring tissue diagnosis; typically ordered after abnormal findings on initial breast imaging (mammography, ultrasound, or MRI).
    • Clinical Circumstances: In patients with newly detected breast lesions, high-risk features on imaging, inconclusive ultrasound-guided biopsy results, or follow-up of previously identified complex lesions.
  • Normal Range
    • Negative Result: Benign histopathology with no malignant cells identified; normal breast tissue, fibroadenoma, fat necrosis, or other clearly benign findings; indicates no cancer present.
    • Reference Standard: Benign lesions classified as BI-RADS 2 (definitely benign) or BI-RADS 3 (probably benign); no atypia or dysplasia present; normal cellular architecture.
    • Measurement Units: Histopathological interpretation using microscopic cellular evaluation; results expressed as diagnostic categories (benign vs. atypical vs. malignant).
    • Normal vs. Abnormal Interpretation: Normal = benign pathology requiring clinical follow-up but no immediate intervention; Abnormal = atypical, suspicious, or malignant findings requiring further management or treatment.
  • Interpretation
    • Benign Findings: Fibroadenoma, papilloma, fat necrosis, fibrocystic changes, or normal tissue; requires routine screening or short-term follow-up imaging (typically 6-12 months); no cancer risk.
    • Atypical/High-Risk Lesions: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), or radial scar; increased cancer risk; often requires surgical excision for complete evaluation and risk management.
    • Malignant Findings: Ductal carcinoma in situ (DCIS) or invasive breast cancer; requires immediate surgical consultation and treatment planning; may involve chemotherapy, radiation, or surgical intervention.
    • Factors Affecting Results: Specimen adequacy, proper tissue preservation, imaging concordance, and pathologist expertise; MRI guidance provides superior accuracy for lesions not visible on other modalities.
    • Clinical Significance: Definitive tissue diagnosis eliminates diagnostic uncertainty; guides treatment intensity and prognosis; determines need for adjuvant therapy and surveillance protocols.
  • Associated Organs
    • Primary Organ System: Breast tissue (mammary gland); involves both glandular and connective tissue components; assesses ductal and lobular structures.
    • Associated Medical Conditions: Breast cancer (ductal or lobular carcinoma); carcinoma in situ; precancerous lesions (atypical hyperplasia); fibroadenoma; papillary lesions; complex cysts.
    • Diseases This Test Helps Diagnose: Invasive breast cancer, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical hyperplasia, high-risk lesions, benign breast disease differentiation.
    • Potential Complications: Minor bleeding or bruising at biopsy site; rare infection; minimal risk of severe complications when performed by experienced radiologists; psychological impact of cancer diagnosis.
    • Risk Factors Associated with Abnormal Results: Age over 40; family history of breast cancer; hormonal factors; dense breast tissue; previous atypical lesions; genetic predisposition (BRCA mutations).
  • Follow-up Tests
    • Benign Results: Routine surveillance mammography in 6-12 months; annual breast imaging thereafter; clinical breast examination; ultrasound if follow-up clarification needed.
    • Atypical Results: Surgical excision often recommended for complete evaluation; repeat MRI or ultrasound after excision; enhanced surveillance with annual mammography and MRI; genetic counseling if indicated.
    • Malignant Results: Immediate surgical oncology consultation; staging studies (chest CT, bone scan, or PET scan if indicated); hormone receptor testing (ER/PR); HER2 status; gene expression profiling; multidisciplinary tumor board review.
    • Additional Imaging: Mammography for better characterization of calcifications; ultrasound for cystic components; MRI for extent of disease assessment; imaging of contralateral breast.
    • Monitoring Frequency: Post-benign diagnosis - every 6-12 months for 2-3 years, then annual imaging; post-atypical diagnosis - enhanced surveillance with MRI annually; post-malignant diagnosis - surveillance per oncology protocol post-treatment.
    • Complementary Tests: Molecular testing (Oncotype DX, Mammaprint) for cancer prognostication; immunohistochemistry for receptor status; genetic testing if BRCA mutation suspected.
  • Fasting Required?
    • Fasting Requirement: No, fasting is not required for MRM breast specimen complex biopsy.
    • Medication Instructions: Continue all regular medications unless specifically instructed otherwise by the radiologist; inform physician of anticoagulant medications (warfarin, aspirin, apixaban) prior to procedure.
    • Pre-Procedure Preparation: Wear comfortable, loose-fitting clothing; remove all metal objects (jewelry, piercings, underwire bras); arrive 15 minutes early for check-in; bring insurance card and photo identification.
    • Timing Considerations: Schedule biopsy during follicular phase of menstrual cycle (first two weeks) if possible; avoid scheduling during menstruation; breast may be tender or swollen during luteal phase.
    • Contraindications: Pregnancy (relative contraindication); pacemakers or metallic implants incompatible with MRI; claustrophobia may require sedation; inability to remain still for 30-45 minutes.
    • Post-Procedure Care: Mild discomfort and bruising expected; ice pack application for 24 hours; wear supportive bra; avoid strenuous activity for 2-3 days; contact physician if excessive bleeding, infection signs, or severe pain develops.

How our test process works!

customers
customers